GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharnext SA (XPAR:ALPHA) » Definitions » Total Current Assets

Pharnext (XPAR:ALPHA) Total Current Assets : €3.87 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Pharnext Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Pharnext's total current assets for the quarter that ended in Dec. 2023 was €3.87 Mil.


Pharnext Total Current Assets Historical Data

The historical data trend for Pharnext's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharnext Total Current Assets Chart

Pharnext Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.65 20.40 15.55 6.15 3.87

Pharnext Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.55 10.68 6.15 3.98 3.87

Pharnext Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Pharnext's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Pharnext's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Pharnext  (XPAR:ALPHA) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Pharnext's Liquidation Value for the quarter that ended in Dec. 2023 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.013-38.123+0.75 * 0.054+0.5 * 0
=-38.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharnext Total Current Assets Related Terms

Thank you for viewing the detailed overview of Pharnext's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharnext (XPAR:ALPHA) Business Description

Traded in Other Exchanges
Address
11-13 Rue Rene Jacques, Issy-Les-Moulineaux, FRA, 92130
Pharnext SA is a biopharmaceutical company developing treatments targeting neurodegenerative diseases. The company also develop a Pleotherapy technology platform. Its product in the pipeline includes SYNGILITY; PXT3003 and PXT864. The company's only segment being research and development on new pharmaceutical therapies based on Pleotherapy.

Pharnext (XPAR:ALPHA) Headlines

No Headlines